A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

NCT06280391 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

312

Enrollment

INDUSTRY

Sponsor class

Conditions

Bronchiectasis

Interventions

DRUG: Itepekimab (SAR440340)
DRUG: Placebo

Sponsor

Sanofi

Collaborators

[object Object]